ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1899

The Intestinal Involvement in Systemic Sclerosis Is Characterized By a Peculiar Gut Microbiota

Silvia Bosello1, Francesco Paroni Sterbini2, Gerlando Natalello1, Giovanni Canestrari1, Federico Parisi1, Maurizio Sanguinetti3 and Gianfranco Ferraccioli4, 1Division of Rheumatology, Università Cattolica - Fondazione Policlinico Universitario A.Gemelli, Rome, Italy, 2Institute of Microbiology, Università Cattolica - Fondazione Policlinico Universitario A.Gemelli, Rome, Italy, 3Institute of Microbiology, Università Cattolica - Fondazione Policlinico Universitario A Gemelli, Rome, Italy, 4Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: microbiome and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gastrointestinal involvement is recognized as a major cause of morbidity and mortality in systemic sclerosis (SSc). The pathophysiology is still unclear and includes impairment of motility, digestion, absorption and excretion. Few data on composition and function of gut micro-environment in SSc are reported in literature but there is a growing body of evidences supporting the hypothesis of a relation between gut microbiota, the host immune system and metabolic/nutritional status. The goal of this study was to characterize the gut microbiota in SSc patients compared to healthy subjects to investigate whether specific microbial species may be responsible of dysbiosis in SSc patients with gastrointestinal involvement. Furthermore, we investigated the composition of microbiota in different subsets of SSc according to patient’s nutritional status to verify if microbiota characteristics may be used as a biomarker for malnutrition and poor prognosis in patients with SSc.

Methods: A total of 66 SSc patients were enrolled: 66.7% presented a normal BMI, 15.1% were underweight, while 18.2% were overweight. Gastrointestinal involvement was evaluated through UCLA-GIT 2.0 questionnaire while nutritional status was assessed through the MUST and selected blood biomarkers (albumin, Vitamin D, Vitamin B12, folate, Ferritin, cholesterol). Faecal samples were obtained from SSc patients and healthy controls. The composition of microbiota was determined through 16S-rRNA pirosequencing performed using the GS Titanium technology (Roche 454). Dedicated statistic (LEfSe) was used to identify taxa that showed differential expression between the groups; α- and β-diversity and Firmicutes/Bacteroidetes ratio were determined.

Results: In our cohort of patients the mean total UCLA GIT 2.0 score was 0.4±0.3. The values representing species richness were significantly different in the SSc group compared to controls (p=0.009 for Shannon index mean values). Noticeably, this difference was mostly accountable to BMI>25 subgroup. Firmicutes/Bacteroidetes ratio was inverted (>1) in the SSc group compared to controls, as already reported in literature for obese patients. At genus level SSc patients showed a differential expression in 21 taxa compared to controls with higher levels of genera such as Ruminococcus, Roseburia, Lactobacillus and Faecalibacterium and a decrease of genera such as Clostridium, Odoribacter, Veillonella and Prevotella. The differences in microbiota composition between SSc patients and controls were supported also by principal coordinate analysis (PCoA) of the values representing phylogenetic distance of microbial communities between specimens. Conversely, there were no substantial differences among subgroups of SSc patients according to BMI and according with the any specific gastrointestinal tract symptoms reported in the questionnaires.

Conclusion: Our analysis demonstrates an altered and distinct composition of gut microbiota in SSc patients compared to healthy controls. This may be the result of the complex pathophysiology of the disease and, at the same time, it may perpetuate immunologic aberrations and contribute to its clinical features. Though in the overweight SSc patients there seems to exist an overlap with the distinctive microbiota of obese patients, no definitive data are available to explain the relation between the nutritional status and gut microbiota in SSc patients.


Disclosure: S. Bosello, None; F. Paroni Sterbini, None; G. Natalello, None; G. Canestrari, None; F. Parisi, None; M. Sanguinetti, None; G. Ferraccioli, Roche, Pfizer, Abbott, 5.

To cite this abstract in AMA style:

Bosello S, Paroni Sterbini F, Natalello G, Canestrari G, Parisi F, Sanguinetti M, Ferraccioli G. The Intestinal Involvement in Systemic Sclerosis Is Characterized By a Peculiar Gut Microbiota [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-intestinal-involvement-in-systemic-sclerosis-is-characterized-by-a-peculiar-gut-microbiota/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-intestinal-involvement-in-systemic-sclerosis-is-characterized-by-a-peculiar-gut-microbiota/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology